Rubicon Research shares make strong debut on D-Street; here's what Anil Singhvi suggests to investors

Rubicon Research IPO Listing: Shares of Rubicon Research Ltd debuted on Dalal Street at around 28 per cent premium over the issue price on Thursday, October 16. The stock of the pharmaceutical formulations company opened for trade at Rs 620 on the NSE and at Rs 620.10 on the BSE, translating to a premium of 27.84 per cent and 27.86 per cent over the issue price, respectively.

The company aimed to raise Rs 1377.50 crore from the public offering of 2.84 crore equity shares.

Listing in line with market guru Anil Singhvi's expectations:

Add Zee Business as a Preferred Source

Earlier on Thursday, Zee Business Managing Editor Anil Singhvi predicted the stock to list in the price range of Rs 600 to Rs 625 against the issue price of Rs 485.

The issue got an amazing response and was subscribed to nearly 104 times.

He advises that short-term investors can keep a stop loss below Rs 575 to protect gains.

Rubicon Research IPO subscription highlights:

Overall, investors bid for 170.96 crore shares against the total shares on offer, with a robust demand from institutional buyers.

The total subscription includes bids from Qualified Institutional Buyers (QIBs), Non-Institutional Investors (NIIs), and Retail Individual Investors (RIIs), who booked the issue 130.26 times, 97.61 times, and 35.47 times, respectively.

In terms of shares, QIBs bid for 116.61 crore shares, NIIs bid for 43.69 crore shares, and RIIs bid for 10.58 crore shares against their allotted portions.

Rubicon Research IPO details:

The Rubicon Research IPO is a book-building issue of Rs 1,377.50 crore, comprising a fresh issue of 1.03 crore equity shares worth Rs 500 crore and an offer for sale (OFS) of 1.80 crore equity shares worth Rs 877.50 crore.

The company plans to utilise the IPO proceeds for debt repayment, funding inorganic growth and for general corporate purposes.

Price band: Rs 461 to Rs 485 per equity share

Face value: Re 1 each

Subscription date: October 9 to October 13, 2025

Lot size: 30 shares

Minimum investment: Rs 14,550 (based on the upper end of the price band)

Rubicon Research company profile:

Rubicon Research Limited is a pharmaceutical formulations company with a strong presence in regulated markets, particularly the United States.

The company has a portfolio of 66 commercialised products and 72 active ANDAs and NDAs approved by the US FDA.